

Digital Therapeutics for Migraine Market to Exceed US \$3.91 Billion by 2029, 23.3% CAGR: The Business Research Company

The Business Research Company's Digital Therapeutics For Migraine Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, November 13, 2025 /EINPresswire.com/ -- What Is The Forecast For The Digital Therapeutics For Migraine Market From 2025 To 2029?



Recent years have seen an explosive increase in the size of the market for digital therapeutics for migraines. The market is predicted to expand from its 2024 value of \$1.37 billion to reach a size of \$1.70 billion in 2025, reflecting a compound annual growth rate (CAGR) of 23.7%. This growth

"

Get 20% Off All Global
Market Reports With Code
ONLINE20 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors"
The Business Research
Company

throughout the history of the market has been driven by heightened demand for healthcare solutions that are tailored to individual needs, a rise in the recognition of migraine as a neurological condition, a greater emphasis on patients managing and monitoring their own conditions, advances in digital health technology, and the broadening availability of telemedicine services.

The <u>digital therapeutics in the migraine treatment market</u> sector is forecasted to experience considerable enlargement in the coming years, swelling to a value of

\$3.92 billion by 2029, with a CAGR of 23.3%. This momentum in growth over the projected timeline can be credited to escalating reliance on digital health solutions, heightened acknowledgment of digital therapeutics amidst healthcare service providers, a surge in patient inclination towards customized treatment alternatives, broadening reimbursement strategies for digital health strategies, and a rise in international healthcare expenditure. Notable trends predicted for this period involve progress in artificial intelligence and machine learning for individualized treatment, amalgamation of digital therapeutics with wearable technology, the creation of mobile health apps for managing migraines, emphasis on proof-based digital health

solutions, and a climbing number of regulatory green lights for digital therapeutics.

Download a free sample of the digital therapeutics for migraine market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=29027&type=smp

What Are The Core Growth Drivers Shaping The Future Of The Digital Therapeutics For Migraine Market?

The surge in smartphone usage is anticipated to boost the expansion of the digital therapeutics for migraine market in the future. Smartphones, which blend telecommunication functionalities with sophisticated computing abilities, internet connectivity and a variety of apps, are seeing an uptick due to their growing affordability and availability. This increase in smartphone usage greatly improves accessibility to digital therapeutics for migraine, encouraging more widespread use of app-based management and treatment solutions. For example, as per the GSM Association (GSMA), a UK-based industry body that represents mobile network operators and businesses, there is expected to be a marked rise in smartphone penetration in sub-Saharan Africa, slated to hit 87% by 2030, a significant jump from 51% in 2022. Consequently, the surge in smartphone use is fuelling the expansion of the digital therapeutics for migraine market.

Which Companies Are Currently Leading In The Digital Therapeutics For Migraine Market? Major players in the Digital Therapeutics For Migraine Global Market Report 2025 include:

- Pfizer Inc.
- Theranica Bio Electronics Ltd.
- Dr. Reddy's Laboratories
- Evidation Health Inc.
- Aptar Digital Health SAS
- Click Therapeutics Inc.
- Salvia BioElectronics B.V.
- Tonix Pharmaceuticals Holding Corp
- Neurolief Ltd.
- AndHealth LLC.

What Are The Key Trends And Market Opportunities In The Digital Therapeutics For Migraine Sector?

Significant players in the <u>digital therapeutics for migraines market size</u> are prioritizing sophisticated innovation, notably prescription-grade mobile software, in order to augment treatment efficiency, promote patient compliance, and meet the growing need for non-pharmaceutical methods of managing migraines. The term ""prescription-grade mobile software"" denotes mobile apps that are both scientifically validated and approved by regulating bodies to offer therapeutic interventions based on solid evidence. For instance, in the month of April 2025, Click Therapeutics, Inc, an American company that concentrates on prescription digital therapeutics, launched CT-132, the inaugural prescription digital therapeutic that was approved by the FDA for preventative treatment of episodic migraines in America. This regulated mobile app is engineered to provide sustainable and effective management of migraines

through software-oriented behavioral strategies, incorporating scientifically validated digital interventions to aid patients in managing migraines triggered by stress and decreasing the number of migraine days per month. Compared to traditional wellness apps, this solution offers superior treatment effectiveness, ensures patient compliance, and facilitates integration into established healthcare systems.

Comparative Analysis Of Leading Digital Therapeutics For Migraine Market Segments The digital therapeutics for migrainemarket covered in this report is segmented –

- 1) By Product Type: Software, Devices, Services
- 2) By Patient Type: Adult, Pediatric
- 3) By Distribution Channel: Healthcare Providers, Online Platforms, Pharmacies
- 4) By Application: Prevention, Acute Treatment, Patient Education, Others Applications
- 5) By End User: Hospitals, Clinics, Homecare, Others End Users

Subsegments:

- 1) By Software: Mobile Applications, Web Applications, Desktop Applications
- 2) By Devices: Wearable Devices, Monitoring Devices, Therapeutic Devices
- 3) By Services: Consultation Services, Coaching Services, Support Services

View the full digital therapeutics for migraine market report: https://www.thebusinessresearchcompany.com/report/digital-therapeutics-for-migraine-global-market-report

Which Regions Are Dominating The Digital Therapeutics For Migraine Market Landscape? In 2024, North America emerged as the dominant region in the global market for digital therapeutics for migraines. It is anticipated that the Asia-Pacific will experience the most rapid growth in the upcoming period. The report encompasses various regions, including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Digital Therapeutics For Migraine Market 2025, By <u>The Business Research Company</u>

Migraine Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/migraine-drugs-global-market-report

Migraine Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Acute Migraine Treatment Global Market Report Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/acute-migraine-treatment-global-market-report

Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

Email: saumyas@tbrc.info

• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham The Business Research Company +44 7882 955267 info@tbrc.info Visit us on social media: LinkedIn Facebook Χ

This press release can be viewed online at: https://www.einpresswire.com/article/866576915

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.